Walmart slides on slower U.S. sales amid Medicaid-driven drug-price shifts
TL;DR Summary
Walmart’s stock dropped about 7% after the retailer reported 2.6% year-over-year U.S. comparable sales growth (excluding fuel) in the quarter, its weakest in years, as pharmacy pressure from changes to Medicare drug-price regulations weighed on results. Revenue rose to $187.9 billion, topping estimates, and Walmart raised its full-year sales guidance to 4%-5%. Analysts highlighted strength in e-commerce, advertising, and other value drivers, even as U.S. pharmacy headwinds linger.
- Walmart shares slide as U.S. sales hit by falling drug prices MarketWatch
- Walmart will report second-quarter earnings before the bell. Here's what to expect CNBC
- Walmart Posts Healthy Quarter, Raises Its 2026 Outlook WWD
- Walmart Posts Weakest Sales Growth in Over Six Years WSJ
- Walmart Posts Slowest Sales Growth in Years as Americans Tighten Wallets The New York Times
Reading Insights
Total Reads
0
Unique Readers
8
Time Saved
24 min
vs 25 min read
Condensed
99%
4,838 → 68 words
Want the full story? Read the original article
Read on MarketWatch